New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
06:53 EDTTHRXTheravance upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Theravance and views risk/reward as favorable ahead of Relvar and Anoro FDA/EMA decisions this year. Price target is $26.
News For THRX From The Last 14 Days
Check below for free stories on THRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
16:13 EDTTHRXTheravance announces Phase 2b study initiated with TD-4208 in COPD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use